Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Santen Pharmaceutical Co ( (JP:4536) ) has shared an update.
Santen Pharmaceutical Co., Ltd. announced a revision of its year-end dividend forecast following a Board of Directors meeting. The company increased its fiscal year-end dividend forecast from 17 yen to 19 yen per share, resulting in a total annual dividend of 36 yen per share for the year ending March 31, 2025. This change reflects Santen’s commitment to returning profits to shareholders, aligned with its progressive dividend policy and medium to long-term earnings prospects.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company focused on eye health, providing products and services to patients, consumers, and medical professionals globally. With a history spanning over 130 years, Santen engages in the research, development, manufacturing, and marketing of pharmaceutical products in ophthalmology, aiming to support eye health worldwide and improve the lives of approximately 50 million people in more than 60 countries.
YTD Price Performance: -1.96%
Average Trading Volume: 1,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.47B
For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.
